Guaifenesin: The Ubiquitous Orphan.

evidence‐based medicine expectorant guaifenesin over‐the‐counter sinonasal

Journal

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
ISSN: 1097-6817
Titre abrégé: Otolaryngol Head Neck Surg
Pays: England
ID NLM: 8508176

Informations de publication

Date de publication:
28 May 2024
Historique:
received: 11 03 2024
accepted: 13 05 2024
medline: 28 5 2024
pubmed: 28 5 2024
entrez: 28 5 2024
Statut: aheadofprint

Résumé

Guaifenesin, a widely used ingredient in over-the-counter cough and cold medications, has been a subject of debate regarding its efficacy in treating respiratory conditions. Despite its historical use and US Food and Drug Administration approval, recent studies have questioned its claimed expectorant effect and its effectiveness in managing symptoms. This article examines the available evidence, highlighting the lack of significant benefits over placebo for upper respiratory disease. The rationale for clinical use is examined alongside the potential downside and alternatives to recommending guaifenesin as a treatment option.

Identifiants

pubmed: 38804670
doi: 10.1002/ohn.834
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 American Academy of Otolaryngology–Head and Neck Surgery Foundation.

Références

Albrecht HH, Dicpinigaitis PV, Guenin EP. Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections. Multidiscip Respir Med. 2017;12:31.
McCoul ED. Assessment of pharmacologic ingredients in common over‐the‐counter sinonasal medications. JAMA Otolaryngol Head Neck Surg. 2020;146(9):810‐815.
Robinson RE, Cummings WB, Deffenbaugh ER. Effectiveness of guaifenesin as an expectorant: a cooperative double‐blind study. Curr Ther Res. 1977;22:284‐296.
Kuhn JJ, Hendley JO, Adams KF, Clark JW, Gwaltney Jr. JM. Antitussive effect of guaifenesin in young adults with natural colds. Chest. 1982;82(6):713‐718.
Wawrose SF, Tami TA, Amoils CP. The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV). Laryngoscope. 1992;102(11):1225‐1228.
Rosen EJ, Calhoun KH. Alterations of nasal mucociliary clearance in association with HIV infection and the effect of guaifenesin therapy. Laryngoscope. 2005;115(1):27‐30.
Albrecht H, Vernon M, Solomon G. Patient‐reported outcomes to assess the efficacy of extended‐release guaifenesin for the treatment of acute respiratory tract infection symptoms. Respir Res. 2012;13(1):118.
Hoffer‐Schaefer A, Rozycki HJ, Yopp MA, Rubin BK. Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections. Respir Care. 2014;59(5):631‐636.
Zhang S, Skinner D, Hicks SB, et al. Sinupret activates CFTR and TMEM16A‐dependent transepithelial chloride transport and improves indicators of mucociliary clearance. PLoS One. 2014;9(8):e104090.
Cho DY, Skinner D, Mackey C, et al. Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(6):629‐637.

Auteurs

Daniel G Eyassu (DG)

Department of Otolaryngology, Tulane University School of Medicine, New Orleans, Louisiana, USA.

Edward D McCoul (ED)

Department of Otolaryngology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Department of Otorhinolaryngology, Ochsner Health, New Orleans, Louisiana, USA.

Classifications MeSH